Income Statement Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:55:00 18/11/2025 GMT			5-day change	1st Jan Change
87.58 ^EUR	-2.57%		+0.89%	-6.57%

11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
11-18	US FDA approves Arrowhead's genetic disorder drug	RE

6c617208eba5e6d583cfa6bb.Nzs_LMH2U9_Yv3l2x9T4tP3tXP0P9OMb9VG9aYITb7c.dUtdXa2CPI-o-SshlJPNh6-MEMpQv9dW2CeLWc1-AvJAXXMZqZ0MiozVDg

Published financial data: SANOFI

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	36.04B	37.76B	43B	43.07B	41.08B
Other Revenues, Total	1.33B	1.41B	2.39B	2.96B	3.2B
Total Revenues	37.37B	39.18B	45.39B	46.03B	44.29B
Cost of Goods Sold, Total	12.1B	12.25B	13.69B	14.22B	13.2B
Gross Profit	25.26B	26.92B	31.7B	31.82B	31.09B
Selling General & Admin Expenses, Total	9.45B	9.6B	10.54B	10.76B	9.25B
R&D Expenses	5.53B	5.69B	6.71B	6.73B	7.39B
Amortization of Goodwill and Intangible Assets - (IS)	1.68B	1.58B	1.83B	2.17B	1.75B
Other Operating Expenses	997M	1.48B	1.59B	2.95B	3.83B
Other Operating Expenses, Total	17.66B	18.35B	20.66B	22.62B	22.22B
Operating Income	7.61B	8.58B	11.04B	9.2B	8.87B
Interest Expense, Total	-459M	-362M	-394M	-527M	-641M
Interest And Investment Income	37M	3M	173M	546M	413M
Net Interest Expenses	-422M	-359M	-221M	19M	-228M
Income (Loss) On Equity Invest.	359M	39M	68M	-115M	60M
Currency Exchange Gains (Loss)	-6M	2M	-4M	-2M	6M
Other Non Operating Income (Expenses)	144M	70M	37M	-665M	-268M
EBT, Excl. Unusual Items	7.68B	8.33B	10.92B	8.44B	8.44B
Restructuring Charges	-1.06B	-820M	-1.34B	-1.49B	-1.4B
Merger & Related Restructuring Charges	-82M	-17M	-3M	-20M	-10M
Gain (Loss) On Sale Of Investments	7.39B	3M	1M	-1M	-
Gain (Loss) On Sale Of Assets	443M	418M	655M	688M	539M
Asset Writedown	-330M	-192M	228M	-896M	-248M
Legal Settlements	-	-	-	-	-470M
Other Unusual Items	124M	115M	27M	318M	-96M
EBT, Incl. Unusual Items	14.16B	7.84B	10.49B	7.04B	6.76B
Income Tax Expense	1.81B	1.56B	2.01B	1.6B	1.2B
Earnings From Continuing Operations	12.35B	6.28B	8.48B	5.44B	5.55B
Earnings Of Discontinued Operations	-	-	-	-	64M
Net Income to Company	12.35B	6.28B	8.48B	5.44B	5.62B
Minority Interest	-36M	-56M	-113M	-36M	-58M
Net Income - (IS)	12.31B	6.22B	8.37B	5.4B	5.56B
Net Income to Common Incl Extra Items	12.31B	6.22B	8.37B	5.4B	5.56B
Net Income to Common Excl. Extra Items	12.31B	6.22B	8.37B	5.4B	5.5B
Per Share Items
Net EPS - Basic	9.82	4.97	6.69	4.31	4.44
Basic EPS - Continuing Operations	9.82	4.97	6.69	4.31	4.39
Basic Weighted Average Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.25B
Net EPS - Diluted	9.77	4.95	6.66	4.3	4.44
Diluted EPS - Continuing Operations	9.77	4.95	6.66	4.3	4.39
Diluted Weighted Average Shares Outstanding	1.26B	1.26B	1.26B	1.26B	1.26B
Normalized Basic EPS	3.8	4.11	5.36	4.19	4.17
Normalized Diluted EPS	3.78	4.09	5.34	4.17	4.15
Dividend Per Share	3.2	3.33	3.56	3.76	3.92
Payout Ratio	31.97	64.41	49.79	82.48	84.6
American Depositary Receipts Ratio (ADR)	0.5	0.5	0.5	0.5	0.5
Supplemental Items
EBITDA	10.5B	11.26B	14.06B	12.52B	11.66B
EBITA	9.32B	10.2B	12.91B	11.43B	10.96B
EBIT	7.61B	8.58B	11.04B	9.2B	8.87B
EBITDAR	10.52B	11.29B	14.09B	12.54B	11.68B
Effective Tax Rate - (Ratio)	12.8	19.88	19.12	22.76	17.82
Total Current Taxes	1.91B	1.91B	2.77B	2.56B	2.15B
Total Deferred Taxes	-99M	-350M	-768M	-958M	-948M
Normalized Net Income	4.77B	5.15B	6.71B	5.24B	5.22B
Interest Capitalized	11M	14M	17M	26M	51M
Interest on Long-Term Debt	49M	49M	57M	65M	93M
Non-Cash Pension Expense	-142M	49M	-25M	50M	-38M
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	5.86B	5.69B	6.71B	6.73B	7.39B
Net Rental Expense, Total	27M	25M	26M	19M	16M
Imputed Operating Lease Interest Expense	4.09M	3.26M	3.92M	4.24M	4.88M
Imputed Operating Lease Depreciation	22.91M	21.74M	22.08M	14.76M	11.12M
Stock-Based Comp., Other (Total)	274M	244M	245M	283M	278M
Total Stock-Based Compensation	274M	244M	245M	283M	278M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	13.92B	10.1B	12.74B	8.71B	7.44B
Short Term Investments	-	-	-	-	-
Trading Asset Securities, Total	-	11M	-	-	115M
Total Cash And Short Term Investments	13.92B	10.11B	12.74B	8.71B	7.56B
Accounts Receivable, Total	7.49B	7.57B	8.42B	8.43B	7.68B
Other Receivables	2.46B	2.22B	2.32B	2.61B	2.95B
Total Receivables	9.95B	9.79B	10.75B	11.04B	10.63B
Inventory	8.35B	8.72B	8.96B	9.67B	9.43B
Prepaid Expenses	525M	615M	714M	768M	895M
Other Current Assets, Total	1.04B	1.43B	955M	486M	14.08B
Total Current Assets	33.79B	30.65B	34.11B	30.67B	42.59B
Gross Property Plant And Equipment	24.88B	27.56B	26.8B	27.44B	26.67B
Accumulated Depreciation	-14.32B	-15.58B	-15.11B	-15.63B	-15.07B
Net Property Plant And Equipment	10.56B	11.98B	11.68B	11.81B	11.6B
Long-term Investments	2.13B	2.42B	2.76B	2.67B	3.26B
Goodwill	44.36B	48.06B	49.89B	49.4B	43.38B
Other Intangibles, Total	12.33B	13.68B	15.41B	18.28B	14.26B
Loans Receivable Long-Term	537M	485M	452M	591M	502M
Deferred Tax Assets Long-Term	4.21B	4.6B	5.38B	6.43B	7.97B
Deferred Charges Long-Term	6.09B	7.73B	6.23B	6.04B	8.37B
Other Long-Term Assets, Total	517M	642M	797M	573M	868M
Total Assets	115B	120B	127B	126B	133B
Liabilities
Accounts Payable, Total	5.3B	6.18B	6.81B	7.33B	7.55B
Accrued Expenses, Total	2.39B	2.55B	2.58B	2.5B	2.37B
Short-term Borrowings	285M	189M	164M	203M	200M
Current Portion of Long-Term Debt	2.48B	3B	4.01B	1.84B	4.02B
Current Portion of Leases	232M	269M	277M	275M	261M
Current Income Taxes Payable	604M	309M	574M	597M	697M
Unearned Revenue Current, Total	252M	319M	264M	-	-
Other Current Liabilities	7.74B	8.48B	9.29B	11.46B	14.07B
Total Current Liabilities	19.28B	21.3B	23.97B	24.21B	29.16B
Long-Term Debt	19.74B	17.12B	14.86B	14.35B	11.79B
Long-Term Leases	931M	1.84B	1.9B	1.76B	1.64B
Pension & Other Post Retirement Benefits	3.5B	2.95B	2.04B	2.21B	1.99B
Deferred Tax Liability Non Current	1.77B	1.62B	1.84B	1.86B	2.17B
Other Non Current Liabilities	6.16B	6.39B	6.96B	7.73B	8.18B
Total Liabilities	51.38B	51.21B	51.57B	52.11B	54.94B
Common Stock, Total	2.52B	2.53B	2.52B	2.53B	2.53B
Additional Paid In Capital	362M	532M	125M	313M	-
Treasury Stock	-705M	-939M	-706M	-1.18B	-840M
Comprehensive Income and Other	60.83B	66.56B	72.84B	72.38B	75.82B
Total Common Equity	63B	68.68B	74.78B	74.04B	77.51B
Minority Interest	146M	350M	368M	313M	350M
Total Equity	63.15B	69.03B	75.15B	74.35B	77.86B
Total Liabilities And Equity	115B	120B	127B	126B	133B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1.25B	1.25B	1.25B	1.25B	1.25B
ECS Total Common Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.25B
Book Value / Share	50.37	54.83	59.7	59.17	61.83
Tangible Book Value	6.31B	6.95B	9.48B	6.36B	19.86B
Tangible Book Value Per Share	5.04	5.55	7.57	5.08	15.84
Total Debt	23.68B	22.42B	21.21B	18.42B	17.91B
Net Debt	9.76B	12.31B	8.48B	9.71B	10.36B
Debt Equivalent of Unfunded Proj. Benefit Obligation	3.32B	2.52B	1.75B	1.94B	1.83B
Debt Equivalent Oper. Leases	216M	200M	208M	152M	128M
Minority Interest, Total (Incl. Fin. Div)	146M	350M	368M	313M	350M
Equity Method Investments, Total	201M	250M	677M	424M	316M
Account Code - Inventory Valuation	3	3	3	3	3
Inventories - Raw Materials, Total	1.05B	1.34B	1.61B	1.68B	1.59B
Inventories - Work In Process, Total	5.4B	5.58B	5.66B	5.87B	5.78B
Inventories - Finished Goods, Total	2.74B	2.7B	2.75B	3.04B	2.9B
Land - (BS)	236M	240M	237M	228M	201M
Buildings, Total	6.83B	7.17B	7.33B	7.68B	7.44B
Machinery, Total	13.65B	14.3B	13.36B	13.41B	12.84B
Full Time Employees	99.41K	95.44K	91.57K	86.09K	82.88K
Assets under Capital Lease - Gross	-	-	-	-	-
Assets under Capital Lease - Accumulated Depreciation	-	-	-	-	-
Accumulated Allowance for Doubtful Accounts (Supple)	142M	137M	113M	95M	100M

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	12.31B	6.22B	8.37B	5.4B	5.56B
Depreciation & Amortization - CF	1.48B	1.38B	1.49B	1.38B	1.02B
Amortization of Goodwill and Intangible Assets - (CF)	1.71B	1.62B	1.87B	2.22B	2.09B
Depreciation & Amortization, Total	3.19B	3B	3.36B	3.61B	3.11B
Amortization of Deferred Charges, Total - (CF)	125M	119M	97M	120M	106M
Minority Interest in Earnings - (CF)	36M	56M	113M	36M	58M
(Gain) Loss From Sale Of Asset	-1.01B	-357M	-573M	-226M	-298M
(Gain) Loss on Sale of Investments - (CF)	-6.88B	-	-	-	-
Asset Writedown & Restructuring Costs	373M	231M	-42M	1.06B	370M
(Income) Loss On Equity Investments - (CF)	-339M	-15M	-48M	295M	82M
Stock-Based Compensation (CF)	274M	244M	245M	283M	278M
Net Cash From Discontinued Operations	-	-	-	-	474M
Other Operating Activities, Total	-303M	-389M	-295M	-1.09B	-44M
Change In Accounts Receivable	-134M	185M	-777M	-397M	-28M
Change In Inventories	-593M	-357M	-927M	-840M	-477M
Change In Accounts Payable	86M	451M	452M	402M	789M
Change in Other Net Operating Assets	316M	1.13B	545M	1.6B	-899M
Cash from Operations	7.45B	10.52B	10.53B	10.26B	9.08B
Capital Expenditure	-1.25B	-1.48B	-1.61B	-1.72B	-1.73B
Sale of Property, Plant, and Equipment	918M	718M	1.49B	1.02B	1.46B
Cash Acquisitions	-5.34B	-5.59B	-992M	-3.87B	-1.9B
Sale (Purchase) of Intangible assets	-860M	-564M	-595M	-1.3B	-1.46B
Investment in Marketable and Equity Securities, Total	10.23B	-311M	-354M	-92M	-623M
Net (Increase) Decrease in Loans Originated / Sold - Investing	-	-	-	-	-
Other Investing Activities, Total	-113M	-68M	-16M	-229M	-149M
Cash from Investing	3.59B	-7.3B	-2.08B	-6.2B	-4.41B
Short Term Debt Issued, Total	282M	-	215M	765M	59M
Long-Term Debt Issued, Total	2.02B	-	1.55B	48M	-
Total Debt Issued	2.3B	-	1.76B	813M	59M
Short Term Debt Repaid, Total	-	-414M	-	-	-
Long-Term Debt Repaid, Total	-4.19B	-2.39B	-3.01B	-3.95B	-953M
Total Debt Repaid	-4.19B	-2.8B	-3.01B	-3.95B	-953M
Issuance of Common Stock	203M	186M	188M	195M	187M
Repurchase of Common Stock	-822M	-382M	-497M	-593M	-302M
Common Dividends Paid	-3.94B	-4.01B	-4.17B	-4.45B	-4.7B
Common & Preferred Stock Dividends Paid	-3.94B	-4.01B	-4.17B	-4.45B	-4.7B
Other Financing Activities, Total	-44M	-48M	-99M	-64M	-50M
Cash from Financing	-6.48B	-7.06B	-5.82B	-8.05B	-5.76B
Foreign Exchange Rate Adjustments	-64M	15M	8M	-32M	-13M
Miscellaneous Cash Flow Adjustments	-	-	-	-	-167M
Net Change in Cash	4.49B	-3.82B	2.64B	-4.03B	-1.27B
Supplemental Items
Cash Interest Paid	315M	334M	380M	559M	587M
Cash Income Tax Paid (Refund)	2.05B	1.28B	2.45B	2.62B	3.29B
Levered Free Cash Flow	6.28B	7.34B	9.01B	8.19B	-4.94B
Unlevered Free Cash Flow	6.57B	7.57B	9.25B	8.52B	-4.54B
Change In Net Working Capital	-345M	-888M	-850M	-1.78B	10.38B
Net Debt Issued / Repaid	-1.88B	-2.8B	-1.24B	-3.14B	-894M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	4.18	4.57	5.59	4.54	4.28
Return on Total Capital	5.53	6.01	7.35	6.08	5.88
Return On Equity %	20.2	9.49	11.77	7.27	7.3
Return on Common Equity	20.2	9.44	11.67	7.26	7.25
Margin Analysis
Gross Profit Margin %	67.61	68.73	69.83	69.12	70.2
SG&A Margin	25.29	24.5	23.22	23.39	20.88
EBITDA Margin %	28.09	28.75	30.98	27.2	26.34
EBITA Margin %	24.93	26.03	28.45	24.82	24.76
EBIT Margin %	20.36	21.9	24.32	19.99	20.03
Income From Continuing Operations Margin %	33.05	16.03	18.69	11.81	12.54
Net Income Margin %	32.95	15.89	18.44	11.73	12.55
Net Avail. For Common Margin %	32.95	15.89	18.44	11.73	12.41
Normalized Net Income Margin	12.76	13.15	14.78	11.38	11.78
Levered Free Cash Flow Margin	16.82	18.75	19.85	17.79	-11.16
Unlevered Free Cash Flow Margin	17.59	19.32	20.39	18.5	-10.26
Asset Turnover
Asset Turnover	0.33	0.33	0.37	0.36	0.34
Fixed Assets Turnover	3.46	3.48	3.84	3.92	3.78
Receivables Turnover (Average Receivables)	4.67	5.02	5.38	5.11	5.1
Inventory Turnover (Average Inventory)	1.48	1.44	1.55	1.53	1.38
Short Term Liquidity
Current Ratio	1.75	1.44	1.42	1.27	1.46
Quick Ratio	1.24	0.93	0.98	0.82	0.62
Operating Cash Flow to Current Liabilities	0.39	0.49	0.44	0.42	0.31
Days Sales Outstanding (Average Receivables)	78.34	72.78	67.88	71.43	71.76
Days Outstanding Inventory (Average Inventory)	247.13	254.24	235.59	239.11	264.85
Average Days Payable Outstanding	155.77	166.02	170.14	172.95	210.1
Cash Conversion Cycle (Average Days)	169.7	161	133.33	137.59	126.52
Long Term Solvency
Total Debt/Equity	37.49	32.47	28.23	24.78	23.01
Total Debt / Total Capital	27.27	24.51	22.01	19.86	18.7
LT Debt/Equity	32.74	27.47	22.3	21.66	17.26
Long-Term Debt / Total Capital	23.81	20.74	17.39	17.36	14.03
Total Liabilities / Total Assets	44.86	42.59	40.7	41.21	41.37
EBIT / Interest Expense	16.58	23.7	28.02	17.46	13.84
EBITDA / Interest Expense	23.52	31.99	36.56	24.31	18.69
(EBITDA - Capex) / Interest Expense	20.79	27.9	32.48	21.05	15.98
Total Debt / EBITDA	2.19	1.94	1.47	1.44	1.5
Net Debt / EBITDA	0.9	1.06	0.59	0.76	0.86
Total Debt / (EBITDA - Capex)	2.48	2.22	1.66	1.66	1.75
Net Debt / (EBITDA - Capex)	1.02	1.22	0.66	0.88	1.01
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-0.7	4.83	15.86	1.42	7.73
Gross Profit, 1 Yr. Growth %	-1.53	6.57	17.73	0.38	9.13
EBITDA, 1 Yr. Growth %	3.34	7.55	24.98	-10.97	5.31
EBITA, 1 Yr. Growth %	3.36	9.75	26.75	-11.49	5.96
EBIT, 1 Yr. Growth %	11.15	13.08	28.87	-16.63	9.21
Earnings From Cont. Operations, 1 Yr. Growth %	320.35	-49.08	35.12	-35.93	8.94
Net Income, 1 Yr. Growth %	338.85	-49.38	34.52	-35.49	2.96
Normalized Net Income, 1 Yr. Growth %	11.57	8.38	30.51	-21.94	14.5
Diluted EPS Before Extra, 1 Yr. Growth %	322.94	-49.28	34.55	-35.44	8.55
Accounts Receivable, 1 Yr. Growth %	-5.62	1.03	11.31	0.11	-8.96
Inventory, 1 Yr. Growth %	4.48	4.35	2.81	7.88	-2.43
Net Property, Plant and Equip., 1 Yr. Growth %	-4.12	13.38	-2.44	1.11	-1.8
Total Assets, 1 Yr. Growth %	1.59	5.09	5.39	-0.2	5.01
Tangible Book Value, 1 Yr. Growth %	3.46K	7.01	36.41	-32.95	212.56
Common Equity, 1 Yr. Growth %	6.9	8.83	8.89	-0.99	4.68
Cash From Operations, 1 Yr. Growth %	-3.81	41.84	0.04	-2.55	-11.47
Capital Expenditures, 1 Yr. Growth %	-5.22	17.94	8.59	7.04	7.04
Levered Free Cash Flow, 1 Yr. Growth %	22.85	16.79	22.8	-9.1	-168.92
Unlevered Free Cash Flow, 1 Yr. Growth %	20.45	15.13	22.38	-7.96	-160.25
Dividend Per Share, 1 Yr. Growth %	1.59	4.06	6.91	5.62	4.26
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	2.34	2.03	10.21	8.4	4.82
Gross Profit, 2 Yr. CAGR %	1.85	2.44	12.01	8.71	4.57
EBITDA, 2 Yr. CAGR %	5.88	5.54	15.91	5.49	-5.61
EBITA, 2 Yr. CAGR %	6.51	6.64	17.91	5.92	-5.41
EBIT, 2 Yr. CAGR %	12.39	12.3	20.68	3.65	-7.57
Earnings From Cont. Operations, 2 Yr. CAGR %	67.1	47.5	-17.05	-6.95	-17.11
Net Income, 2 Yr. CAGR %	69.11	50.32	-17.48	-6.85	-18.5
Normalized Net Income, 2 Yr. CAGR %	11.84	10.15	18.89	0.93	-8.98
Diluted EPS Before Extra, 2 Yr. CAGR %	68.53	47.67	-17.39	-6.8	-16.85
Accounts Receivable, 2 Yr. CAGR %	1.58	-2.35	6.04	5.56	-4.54
Inventory, 2 Yr. CAGR %	5.69	4.41	3.58	5.31	2.59
Net Property, Plant and Equip., 2 Yr. CAGR %	4.62	4.26	5.17	-0.68	-0.36
Total Assets, 2 Yr. CAGR %	1.39	3.32	5.24	2.55	2.37
Tangible Book Value, 2 Yr. CAGR %	58.72	338.1	20.82	-4.36	44.77
Common Equity, 2 Yr. CAGR %	3.44	7.84	8.86	3.83	1.8
Cash From Operations, 2 Yr. CAGR %	15.88	16.78	19.12	-1.26	-7.12
Capital Expenditures, 2 Yr. CAGR %	-5.86	5.73	13.17	7.85	6.46
Levered Free Cash Flow, 2 Yr. CAGR %	22.8	19.88	19.73	5.65	-23.8
Unlevered Free Cash Flow, 2 Yr. CAGR %	21.36	17.85	18.68	6.13	-28.01
Dividend Per Share, 2 Yr. CAGR %	2.1	2.82	5.48	6.26	4.93
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	1.05	3.17	6.45	7.2	4.17
Gross Profit, 3 Yr. CAGR %	0.66	3.4	7.3	7.99	4.91
EBITDA, 3 Yr. CAGR %	0.7	6.36	11.61	6.16	1.21
EBITA, 3 Yr. CAGR %	0.57	7.49	12.91	7.16	2.48
EBIT, 3 Yr. CAGR %	1.52	12.5	17.51	6.68	1.17
Earnings From Cont. Operations, 3 Yr. CAGR %	46.92	12.39	43.25	-23.89	-4.01
Net Income, 3 Yr. CAGR %	13.53	13.06	44.86	-23.98	-3.69
Normalized Net Income, 3 Yr. CAGR %	2.98	10.56	16.5	3.33	0.48
Diluted EPS Before Extra, 3 Yr. CAGR %	48.56	12.9	43.16	-23.91	-3.92
Accounts Receivable, 3 Yr. CAGR %	1.25	1.39	2	4.03	0.48
Inventory, 3 Yr. CAGR %	7	5.24	3.88	4.99	2.67
Net Property, Plant and Equip., 3 Yr. CAGR %	3.31	7.46	1.98	3.8	-1.05
Total Assets, 3 Yr. CAGR %	4.69	2.58	4.01	3.39	3.37
Tangible Book Value, 3 Yr. CAGR %	0.57	40.52	196.94	-0.71	41.93
Common Equity, 3 Yr. CAGR %	2.75	5.27	8.19	5.47	4.11
Cash From Operations, 3 Yr. CAGR %	0.32	23.79	10.91	11.41	-4.79
Capital Expenditures, 3 Yr. CAGR %	-3.33	1.49	6.67	11.09	5.45
Levered Free Cash Flow, 3 Yr. CAGR %	-16.6	20.79	20.8	9.23	-12.33
Unlevered Free Cash Flow, 3 Yr. CAGR %	-15.91	19.27	19.3	9.04	-15.62
Dividend Per Share, 3 Yr. CAGR %	1.84	2.75	4.16	5.52	5.59
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	1.4	2.46	4.62	5.23	3.31
Gross Profit, 5 Yr. CAGR %	1.08	2.33	5.05	5.49	3.92
EBITDA, 5 Yr. CAGR %	0.51	1.69	6.47	5.98	2.89
EBITA, 5 Yr. CAGR %	-0.64	2.02	7.11	6.83	4.1
EBIT, 5 Yr. CAGR %	1.77	2.67	8.7	8.84	5.45
Earnings From Cont. Operations, 5 Yr. CAGR %	22.31	6.96	16.85	4.21	13.99
Net Income, 5 Yr. CAGR %	23.49	5.73	-0.11	4.63	15.09
Normalized Net Income, 5 Yr. CAGR %	3.5	3.09	8.98	6.57	4.21
Diluted EPS Before Extra, 5 Yr. CAGR %	23.95	7.87	17.45	4.56	14.1
Accounts Receivable, 5 Yr. CAGR %	0.28	0.69	3.14	3.04	-0.66
Inventory, 5 Yr. CAGR %	5.09	4.79	5.62	5.27	3.36
Net Property, Plant and Equip., 5 Yr. CAGR %	1.22	3.63	4.05	4.13	1.04
Total Assets, 5 Yr. CAGR %	2.28	2.81	4.89	2.57	3.35
Tangible Book Value, 5 Yr. CAGR %	-4.69	-2.15	8.86	20.47	122.78
Common Equity, 5 Yr. CAGR %	1.65	3.6	5.19	4.69	5.59
Cash From Operations, 5 Yr. CAGR %	-3.54	6.07	7.36	13.08	3.31
Capital Expenditures, 5 Yr. CAGR %	0.83	3.94	2.96	3.97	5.55
Levered Free Cash Flow, 5 Yr. CAGR %	22.55	5.03	-3.62	14.46	-0.66
Unlevered Free Cash Flow, 5 Yr. CAGR %	21	4.86	-3.48	13.81	-3.58
Dividend Per Share, 5 Yr. CAGR %	1.78	2.38	3.28	4.14	4.47